← All trials
NCT01952223
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2013
- Primary completion
- Sep 1, 2019
- Completion date
- Sep 1, 2026
- First posted
- —
- Last posted
- —
- Enrollment
- 1048
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- UNICANCERLead sponsor
- Fundación Althaia ManresaOverall official - principal investigator
- Hospital Universitario Lucus AugustiOverall official - principal investigator
- Institut de Cancérologie de LorraineOverall official - principal investigator
- Universidad Complutense de MadridOverall official - principal investigator
- Universidad Autonoma de BarcelonaOverall official - principal investigator
- University of BarcelonaOverall official - principal investigator
- University of MilanOverall official - principal investigator
- Centre Catherine de Sienne - NantesOverall official - principal investigator
- L'Institut Mutualiste Montsouris-ParisOverall official - principal investigator
- Institut Gustave RoussyOverall official - principal investigator
- RocheOverall official - principal investigator
- University of SalamancaOverall official - principal investigator
- University of RennesOverall official - principal investigator
- University of StrasbourgOverall official - principal investigator
- University of ReimsOverall official - principal investigator
- University of CorunaOverall official - principal investigator
- Clinique PasteurOverall official - principal investigator
- Institut de Cancerologie de l'Ouest Paul PapinOverall official - principal investigator
- Groupe Hospitalier Paris Saint JosephOverall official - principal investigator
- University of MalagaOverall official - principal investigator
- Corporacion Parc TauliOverall official - principal investigator
- Universidad de CordobaOverall official - principal investigator
- Centre Hospitalier de Saint-BrieucOverall official - principal investigator
- Centre hospitalier de MulhouseOverall official - principal investigator
- University of ToulouseOverall official - principal investigator
- University of Texas at HoustonOverall official - principal investigator
- University of SevilleOverall official - principal investigator
- Centre Jean PerrinOverall official - principal investigator
- Centre Leon BerardOverall official - principal investigator
- Badalona Hospital Germans Trias i PujolOverall official - principal investigator
- University of ParisOverall official - principal investigator
- Curie InstituteOverall official - principal investigator
- Institut Paoli-CalmettesOverall official - principal investigator
- University of LimogesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.